Teva To Trasfer Listing To NYSE By May 2012; Watson Near To $7 billion Actavis Drug Agreement
Thu, 03/22/2012 - 06:37 | 
Teva Pharmaceutical Industries Ltd stated that it is moving its listing of U.S. traded shares to NYSE from the Nasdaq Global Select Market by May 2012.
A federal advisory board on March 20 disapproved the experimental medicine, ridaforolimus, produced by Ariad Pharmaceuticals (ARIA) and joined hands with Merck & Co. (MRK), for utilization in patients with soft-tissue or bone sarcomas.
GlaxoSmithKline and Johnson & Johnson have joined hands with venture capital company Index Ventures to introduce a fund to make investment in life sciences firms, continuing Big Pharma's push to tap into novel drugs while bringing down the billions it has historically expended on internal research and growth.
Tags: Andrew Forced To Enhance NHS Negligence Funding; Amag Q4 Sales To Miss Anticipations
Andrew Lansley has been forced to offer up an added £185 million boost to assist the NHS fund legal battles because of growing numbers of carelessness claims.
Pain pills such as Percocet and Opana from Endo Pharmaceuticals may be in short supply after their fabrication plant was closed for production as well as quality concerns.
Ariad Pharmaceuticals’s scrip had its “outperform” ranking reaffirmed by research forecasters at Rodman & Renshaw in a report released on January 14.
Amag Pharmaceuticals stated that it anticipates its fourth quarter earnings to miss Street expectations, though it repeated its full year financial 2012 viewpoint.
